Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration

Kinesia-D Phase II In-Clinic Continuous Assessment Study

The objective is to assess a compact, portable, wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced dyskinesia in Parkinson's disease.

Inclusion Criteria:

• Diagnosis of idiopathic Parkinson's disease
• Clinical history of levodopa-induced dyskinesia
• 21 Years of age or older
• Stage 2 - 4 OFF-medication on the Hoehn and Yahr scale

Exclusion Criteria:

• Dementia (determined by a neuropsychological assessment)
• Severe tremor unaffected by levodopa